Metabolism of Propofol in humans
Conditions
Interventions
Group 1: Patients will be included who require balanced general anesthesia and have an indication for arterial invasive blood pressure monitoring and a bladder catheter. Blood samples will be taken th
Sponsors
Universität des Saarlandes
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Indication for balanced general anesthesia with a presumed operation duration of at least 300 minutes - An indication for an invasive arterial blood pressure measurement and an indwelling bladder catheter independent of the study - Signed patient information and patient consent
Exclusion criteria
Exclusion criteria: - Total intravenous anesthesia (TIVA) - Liver and/or kidney dysfunction - Tumor disease - Pregnancy - Infectious disease (hepatitis, HIV)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The investigation of the known propofol metabolites in humans in plasma and urine after intravenous bolus administration. The aim is to check whether all previously described metabolites of propofol are detectable in plasma and urine in humans, what percentage distribution exists and how great the variability between individual patients is. | — |
Secondary
| Measure | Time frame |
|---|---|
| A pharmacogenetic analysis of the patients in order to explain possible different metabolism patterns. These analyses will be carried out in cooperation with the Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP, Prof. Schwab), Bosch Health Campus Stuttgart. | — |
Countries
Germany
Contacts
Public ContactTobias Hüppe
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie
Outcome results
None listed